Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001551956 | SCV001772564 | uncertain significance | not provided | 2019-08-20 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect |
Labcorp Genetics |
RCV001551956 | SCV002365975 | likely benign | not provided | 2024-12-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002568335 | SCV003730178 | uncertain significance | Inborn genetic diseases | 2024-06-30 | criteria provided, single submitter | clinical testing | The c.1717T>C (p.S573P) alteration is located in exon 16 (coding exon 15) of the CLCNKB gene. This alteration results from a T to C substitution at nucleotide position 1717, causing the serine (S) at amino acid position 573 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005040317 | SCV005683438 | uncertain significance | Bartter disease type 3; Bartter disease type 4B | 2024-02-09 | criteria provided, single submitter | clinical testing |